Company ProfilePremium

Aju IB Investment Co., Ltd.

Company Profile Analysis

Ticker: 027360.KQ주식회사 아주아이비투자

ESOMAR 23 Corporate BadgeISO Certifications Badge
Aju IB Investment Co., Ltd. - Company showcase

Year Founded & Workforce

1974

53 Employees

Aju IB Investment Co., Ltd. logo

Aju IB Investment Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Aju IB Investment Co., Ltd. Overview

Aju IB Investment is Korea's oldest venture capital firm, originating in 1974 as a KIST-funded technology-commercialisation vehicle. It is now the alternative-investment arm of the mid-sized Aju Group. The firm manages roughly KRW 2.5 trn of third-party capital across venture funds and private equity vehicles. It invests across the full lifecycle, from accelerator-stage seed deals through growth venture rounds to control buyouts such as the 2026 acquisition of airport-lounge platform E-Bridge. Its distinguishing asset is a decade-old US platform: Solasta Ventures in Boston (biotech) and Solasta Nexus in Silicon Valley (deep tech). Through these, it reports 19 Nasdaq portfolio listings and holds an undisclosed stake in SpaceX. Earnings combine a steady management-fee base with highly cyclical performance fees and mark-to-market gains. This produced a record 1H 2026, followed by an 85% share-price collapse from its April 2026 peak.


What the company does

Aju IB Investment is a fund manager and principal investor. It raises capital from limited partners (LPs), including the National Pension Service, the Korea Development Bank's growth funds, Korea Venture Investment Corp. (Fund of Funds), mutual-aid associations and corporates. It deploys that capital into unlisted Korean and US companies through venture funds (투자조합) and private equity funds (사모투자합자회사). As general partner, the company commits its own balance-sheet capital (the "GP commitment") alongside LPs. It also invests directly from its proprietary account. It earns returns through four channels:

  1. Management fees (관리보수): recurring fees on committed or invested capital. 1H 2024 management fees were KRW 9.13 bn (Asiae CORE, 14 Aug 2024).

  2. Performance fees (성과보수, carried interest): paid when a fund is liquidated with an IRR above its hurdle. These were KRW 10.2 bn in FY2023 and KRW 4.5 bn in FY2024 (Dealsite, 16 May 2025).

  3. Equity-method income (지분법이익): the company's share of profits in funds it does not consolidate, generally where its stake is below 20% (Dealsite, 15 May 2019).

  4. Investment-asset gains (투자자산관련수익): fair-value and disposal gains on proprietary and consolidated-fund holdings, recognised as FVTPL (fair value through profit or loss).

By 1Q 2026 revenue composition, Butler reports equity-method income at 35%, management fees at 24%, performance fees at 21%, investment-asset income at 15% and other operating revenue at 5%.

Revenue model characterisation

The revenue model is almost entirely service-and-carry plus principal investment returns. There is no product, subscription or licensing revenue. Management fees act as an annuity-like floor. Performance fees and fair-value gains create large swings tied to IPO windows on KOSDAQ and Nasdaq. The company said in early 2025 that most of its exits are realised through KOSDAQ, so a KOSDAQ decline of more than 20% in 2024 fed directly into weaker results (Dealsite, 14 Feb 2025).

Value-chain position, customers and end-markets

Aju IB sits between institutional capital providers (its "customers" as LPs) and investee companies. Its end-markets are the sectors it invests in:

Biotech and healthcare: both in Korea and through Solasta Ventures in Boston.

Deep tech and ICT: AI, robotics, cloud, autonomous mobility, space and semiconductors, via Solasta Nexus and Korean funds.

Materials, parts and equipment (소부장): for example Nextil and Nanoteam.

Consumer and platform businesses: for example Yanolja, Delicious and E-Bridge.

Mid-market buyouts: through the Aju Good PEF series.

Company self-description vs independent characterisation

In public statements, the company describes itself as an alternative-investment specialist. It emphasises its full-cycle pipeline from accelerator through VC to PE, and its first-generation track record (Asiae CORE, 27 Aug 2026). CEO Kim Ji-won has repeatedly framed the strategy as balancing domestic and overseas investing, and VC with PE, to build a stable earnings structure (Dealsite, 2 Feb 2021).

Independent characterisation: Aju IB is a mid-to-large Korean VC/PE house. Its listed equity is effectively a levered call option on (a) KOSDAQ IPO conditions, (b) a handful of large US positions (historically Arcellx, Kymera and Atea; currently SpaceX and a set of AI infrastructure names), and (c) fundraising success under Korea's expanding policy-capital programmes such as the National Growth Fund. The fee base, roughly KRW 18–20 bn per year, covers operating costs of about KRW 16 bn in SG&A. Profitability above breakeven therefore depends on realisations and marks.

Strategy

Stated strategic themes

Recurring themes in management statements are:

  1. Full-cycle investing: from accelerator through VC to PE (Asiae CORE, 27 Aug 2026).

  2. Global platform: Boston for biotech, Silicon Valley for deep tech, and Japan through LP positions.

  3. AUM scale-up: to expand the management-fee floor and reduce reliance on markets. The CEO said in May 2025 that the firm would not rely solely on market conditions (Asiae English, 16 May 2025).

  4. Balanced earnings mix: across domestic and overseas, VC and PE (Dealsite, 2 Feb 2021).

  5. Shareholder value: steady dividends and AUM-driven earnings growth.

Initiatives in the last 24 months

InitiativeTimingDetailSource
Solasta Nexus incorporationAnnounced Feb 2025; completed Jun 2026Silicon Valley branch converted to an entity; dedicated frontier-tech fundDealsite, 14 Feb 2025; Asiae CORE, 27 Aug 2026
Solasta Nexus Frontier-Tech Fund2025–26KRW 50 bn target; AI, digital transformation, robotics, space and climateAsiae CORE, 18 Jun 2025
Aju Good Venture Fund 3.02,025KRW 200 bn+ target; KRW 182 bn LOCs securedDealsite, 16 May 2025
Aju Good No.4 PEFDec 2025 – Mar 2026Closed at KRW 316 bnAsiae, 14 Aug 2026
E-Bridge buyoutSPA Dec 2025; closing Apr 2026~KRW 250 bn; first control deal from No.4; plans for overseas network and tie-ups with conglomerate retail and tourism affiliates; exit options include IPODealsite, 11 Feb 2026
Accelerator DivisionJan 2026First large Korean VC to run AC as a full divisionAsiae CORE, 27 Aug 2026
National Growth Fund GP1H 2026KRW 43 bn commitment (small-league indirect investment, Shinhan AM-managed); Super-Gap Scale-up 2.0 target KRW 200 bnAsiae CORE, 27 Aug 2026
Teachers' Pension (사학연금) shortlistJul 2026Potential matching capital for the 2.0 fundDealsite, 22 Jul 2026
Japan LP programme2,025First commitments to Japanese VC fundsAsiae CORE, 27 Aug 2026
Accelerated deployment1H 2026~KRW 150 bn invested; dry powder fell from KRW 283.4 bn to KRW 134.5 bn, positioning for new fund closesDealsite, 22 Jul 2026

ESG and cost programmes

No sustainability-linked commitments or formal cost-reduction programmes with targets were identified.

Medium-term targets and guidance

No numeric earnings guidance was identified. Qualitative and operational targets include:

  • About KRW 500 bn of new fund capacity from Venture Fund 3.0, No.4 PEF and Frontier-Tech (May 2025 plan; Dealsite, 16 May 2025).

  • More than ten portfolio IPOs in 2H 2026 (Asiae, 14 Aug 2026).

  • Average fundraising of about KRW 150 bn per year (six funds totalling KRW 741.8 bn over five years), to be lifted by the 2.0 fund (Asiae CORE, 27 Aug 2026).

Products & Services

Aju IB's "products" are its funds and investment programmes. The catalogue below lists every fund vehicle identified in public sources. Committed size is shown in KRW where disclosed. Management-fee rates and carry terms are not publicly disclosed for individual funds.

Venture capital funds (domestic)

FundYearSizeTarget / notesStatus
Aju Good Venture Fund (아주 좋은 벤처펀드)2,017KRW 100 bnGeneralist venture—
Aju Good Venture Fund 2.0——Generated KRW 1.5 bn of fees in 1H 2023Active (Dealsite, 16 Aug 2024)
Aju Good Venture Fund 3.02,025Target KRW 200 bn+; KRW 182 bn LOCs by May 2025 from NPS, POBA and Science & Technology mutual-aid associationFlagship VC fund—
Aju Good Growth Support Fund (아주좋은성장지원펀드)2,018KRW 175 bnGrowth stageActive (Dealsite, 15 May 2019)
NH-Aju KOSDAQ Scale-up Fund2,019KRW 106 bnKOSDAQ scale-up co-GP with NH—
Aju Good Super-Gap Scale-up Fund (초격차 스케일업펀드)Dec 2023 / 2024KRW 60 bn first close, KRW 100 bn totalDeep-tech "super-gap" sectorsInvesting (Dealsite, 15 Feb 2024 & 16 May 2025)
Aju Good Super-Gap Scale-up 2.0 Fund2026 (forming)Target KRW 200 bn hard cap; KRW 43 bn National Growth Fund commitment; possible Teachers' Pension matchingLead manager: Park Se-geunFundraising (Asiae CORE, 27 Aug 2026; Dealsite, 22 Jul 2026)
Policy-type New Deal Fund2,021Target KRW 150 bnDigital/green New Deal; NPS matching—
Aju Good Growth 2 Fund (아주좋은그로쓰2호)——Holds NanoteamHarvesting (Dealsite, 16 May 2025)
Aju Good Technology Finance Fund (기술금융 펀드)——Equity-method income of KRW 4.0 bn in 1Q 2023Active (Dealsite, 28 May 2024)
Aju Growth & Healthcare Fund~2017—Invested in Gridwiz Series BActive (Dealsite, 14 Aug 2024)
Aju Early Commercialisation Fund (아주초기사업화투자조합)2,016KRW 25 bnEarly stage; Gridwiz Series ALiquidated 2024 (Dealsite, 16 May 2025)
2014 KIF-Aju IT Fund2,014KRW 31 bnICTLiquidated 1H 2024
Aju Digital Contents Fund—KRW 26 bnContentLiquidated 1Q 2025 (Dealsite, 16 May 2025)
IBKC-Aju IB IDiscovery Fund 1—KRW 7.2 bnCo-GP with IBK CapitalLiquidated 1Q 2025
Aju December Nox Fund2,023KRW 24.8 bnProject fundActive (Dealsite, 15 Feb 2024)

Overseas-dedicated funds

FundYearSizeFocusStatus
Aju Life Science Overseas Expansion Platform Fund—Part of KRW 215 bn combinedUS biotechActive as of Jan 2021
Aju Growth & Healthcare—Part of KRW 215 bn combinedCross-border healthcareActive as of Jan 2021
Aju Good Life Science 3.0Jul 2018KRW 123 bnUS biotech via SolastaActive (Dealsite, 2 Jul 2019)
Aju Life Science 4.02,021Planned KRW 100 bn+; Aju Industrial committed KRW 10 bnUS biotech—
Solasta Nexus Frontier-Tech Fund2025–26 (forming)Target KRW 50 bnAI, digital transformation, robotics, space and climate techFundraising (Asiae CORE, 18 Jun 2025; Dealsite, 16 May 2025)

Private equity funds

FundYearSizeNotable holdings / notesStatus
Aju Good PEF (아주좋은 사모투자합자회사)2,017KRW 250 bnYanolja; Point Mobile (28.3% with overseas fund, 2020)Harvesting; top fee contributor in FY2023 at KRW 7.4 bn (Dealsite, 16 May 2025)
Aju Good PEF No.2~2019–20KRW 136 bn first close, expandingPoint Mobile sourcing7 Jan 2021)
Aju Good PEF No.32,023KRW 267.9 bnMid-marketInvesting (Dealsite, 15 Feb 2024)
Aju Good No.4 PEFDec 2025 / Mar 2026KRW 316 bn after second close; anchored by KDB Innovation Growth Fund (KRW 100 bn) and Korea EximbankFirst deal: E-BridgeInvesting (Asiae, 14 Aug 2026; Dealsite, 11 Feb 2026)
Aju E-Bridge Fund2,026KRW 146.4 bnProject fund co-investing in E-BridgeInvested
NH-Aju IB SME/Mid-cap Growth 2013 PEF2,013KRW 200 bnMid-cap growthLiquidated 2024
Wonik-Aju Turnaround No.1 PEF—KRW 47 bnTurnaround; Nextil HoldingsLiquidated 2024

Proprietary and direct investment

The company also invests from its own account. For example, it held 6.05% of HNS Hitech directly on balance sheet in 2024 (Dealsite, 14 Aug 2024). FVTPL financial assets on the consolidated balance sheet were KRW 129.7 bn at 30 June 2026, up from KRW 89.4 bn at end-2025 (Valueline).

Flagship portfolio companies (named in public sources)

CompanyCountrySectorStatus / outcome
SpaceXUSSpace / satellite (merged with xAI Feb 2026)Invested 1H 2023 via Solasta SPV; listed on Nasdaq 12 Jun 2026; stake undisclosed
ArcellxUSCAR-T cell therapyKRW 17.4 bn invested; KRW 167.5 bn recovered (~10x); Gilead acquisition agreed Feb 2026 for USD 7.8 bn
Kymera TherapeuticsUSTargeted protein degradationKRW 5.7 bn → KRW 64.1 bn
Atea PharmaceuticalsUSAntiviralsKRW 9.2 bn → KRW 92.5 bn
SeerUSProteomicsNasdaq IPO Dec 2020
Apellis PharmaceuticalsUSComplement therapeuticsListed; realisation details not disclosed
Rescale, Cohere, Lambda, DatabricksUSCloud HPC, generative AI, AI cloud, data analyticsHeld via Silicon Valley platform (Herald, 28 Apr 2026)
Ridecell, Tibit CommunicationsUSAutonomous mobility platform, telecom equipmentSilicon Valley portfolio (Dealsite, 26 Jan 2021)
YanoljaKoreaTravel platformInvested 2017; IPO delayed; SoftBank valued it at KRW 8 trn in 2021
KraftonKoreaGamesInvestment cited as a share-price catalyst in 2020–21
Pearl AbyssKoreaGamesKRW 2 bn → KRW 11 bn
NextilKoreaSeamless steel pipe~4x / IRR 45%
NanoteamKoreaMaterials/partsIPO Mar 2023 at KRW 13,000; trading ~KRW 5,270 (Aug 2026)
Udang TechnologyKoreaIndustrialSold to TKG Aekang; IRR 26%; KRW 55 bn sale, KRW 71.5 bn total recovery
Gridwiz, Laser Optek, HNS Hitech, Organoid Sciences, Inventage Lab, Next Biomedical, Onconic Therapeutics, DotmillKoreaEnergy, devices, biotechIPOs/listings 2024–25
Canaf Therapeutics, IM Biologics, Mezoo, Lemon Healthcare, DeliciousKoreaBiotech, digital health, fashion B2BIPOs Jan–Aug 2026
Dabeeo, PGT, MBD, NexIKoreaSpatial AI, specialty chemicals, organoid medicine, immuno-oncologyIPO pipeline 2H 2026
E-BridgeKoreaAirport lounge platform ("The Lounge")100% buyout, ~KRW 250 bn
DeepX, Hutom, Sizzle, Bonzak, Pebble-i, Kovis Technology, SigGenGuru, Hurotics, HomecheckKoreaAI chips, surgical AI, othersPart of ~200 companies invested since 2015 (Dealsite, 6 Feb 2025)

Financial Narrative

Income statement

Revenue is operating revenue (영업수익). Gross profit and EBITDA are not reported by Korean financial-company formats and are not meaningful for a VC.

Sources: FY2021–FY2025 revenue, OI and NI from Butler (company page 00156895). FY2023 and FY2024 confirmed against Dealsite (15 Feb 2024; 16 May 2025; 27 Mar 2025). FY2025 pre-tax income from Valueline. EPS is derived as NI divided by year-end shares (120.82 m, 120.82 m, 120.85 m, 120.95 m, 121.15 m), not reported diluted EPS. FY2025 DPS from ETFShopping.

Extended history (for context):

Sources: FY2019 and FY2020 from Dealsite (12 Feb 2020; 2 Feb 2021). FY2018 is derived from reported FY2019 growth rates (revenue −12%, OI +45%, NI +38.5%).

Revenue CAGR. FY2021–FY2024 revenue CAGR was −22.2% (derived). The FY2021 base was inflated by the 2020–21 IPO boom. On an FY2019–FY2024 basis, revenue grew at about +0.5% per year (derived: 64.1 → 65.6), which illustrates the cyclicality.

FY2025 and trailing income detail

Source: Valueline consolidated income statement (TTM columns at 2025/12 and 2026/06).

Quarterly operating income (derived)

Sources and method: Q1 2024 (KRW 6.3 bn), 1H 2024 (KRW 10.8 bn), 9M 2024 (KRW 10.8 bn), Q1 2025 (KRW 0.77 bn), Q1 2026 (KRW 8.1 bn) and Q2 2026 (KRW 38.1 bn) are reported (Dealsite, Asiae). The remaining quarters are derived from FY totals and Valueline TTM columns (TTM OI: 2025/03 KRW 2.87 bn; 2025/06 KRW 1.44 bn; 2025/09 KRW 3.78 bn; 2025/12 KRW 11.88 bn; 2026/06 KRW 54.21 bn). The derived quarters reconcile to the reported annual figures.

Commentary on income trends

FY2021 (peak cycle): OI of KRW 52.0 bn and NI of KRW 39.3 bn followed the record FY2020 (OI KRW 63.1 bn). Both years benefited from a domestic IPO boom (nine portfolio IPOs in 2020) and Nasdaq biotech listings. Management said more than 30% of 2020 investment gains came from overseas (Dealsite, 2 Feb 2021).

FY2022 (trough): OI collapsed 91% to KRW 4.8 bn and NI to KRW 2.0 bn as listed valuations fell and fair-value marks turned negative.

FY2023 (recovery): Exits at Nextil (~4x), Nanoteam (KRW 22.3 bn partial sale) and Corelinesoft, plus rising management fees from new PEF No.3, lifted OI to KRW 17.7 bn (+266%) and NI to KRW 16.6 bn (+714%) (Dealsite, 15 Feb 2024).

FY2024 (relapse): Performance fees fell 56% to KRW 4.5 bn. SG&A rose KRW 1.3 bn to KRW 16.9 bn, and total operating expenses reached KRW 57.2 bn. KOSDAQ fell more than 20%, producing a 4Q operating loss. OI halved to KRW 8.4 bn (Dealsite, 16 May 2025). Gains on Arcellx and Udang Technology partly offset the decline.

FY2025: A weak 1H (Q1 OI KRW 0.8 bn, hit by tariff-driven market declines) was followed by a stronger 2H. OI reached KRW 11.9 bn and NI was flat at KRW 8.3 bn. Operating cash flow was slightly negative at −KRW 1.1 bn (Valueline TTM).

1H 2026 (inflection): OI of KRW 46.2 bn already exceeded every full year since FY2021. Drivers were higher performance fees, SpaceX fair-value gains and the Arcellx disposals following the Gilead bid (Asiae, 14 Aug 2026). 1H 2026 NI was about KRW 36.2 bn (Valueline balance-sheet line for current-period NI). TTM ROE reached 13.9% (Valueline).

Balance sheet

Source: Valueline consolidated balance sheet. FY2021 balance-sheet detail was not available in the sources reviewed.

Notes:

  • Net debt is derived as total borrowing liabilities less cash and deposits. "Other borrowing liabilities" may include lease liabilities and borrowings at consolidated fund level.

  • The balance sheet is unclassified (financial-company format), so working capital is not meaningful.

  • Treasury shares fell to zero by 30 June 2026 while capital surplus rose from KRW 20.8 bn to KRW 23.3 bn. This indicates the treasury stock was disposed of rather than cancelled.

Balance-sheet commentary. Aju IB has de-levered steadily. Total borrowing liabilities fell from KRW 95.6 bn (FY2022) to KRW 30.3 bn (2Q 2026). Total liabilities to equity fell from 53% to 22% (derived). Equity has compounded slowly, from KRW 243.4 bn to KRW 266.9 bn over FY2022–FY2025, constrained by low earnings and dividends. It then jumped KRW 32.4 bn in 1H 2026 on the record profit.

The asset base is dominated by two pools. Equity-method stakes in its own funds (~KRW 144 bn) are the GP commitments. FVTPL holdings (~KRW 130 bn) include consolidated-fund and proprietary positions. The jump in FVTPL assets and deferred tax liabilities in 1H 2026 is consistent with large unrealised gains, notably SpaceX. These gains remain exposed to market reversal. SpaceX shares fell roughly 50% from their post-IPO peak by late July 2026 (Wikipedia, SpaceX IPO article).

Cash flow

Source: Valueline cash-flow page (TTM columns).

Capex is immaterial for the business: PP&E was KRW 4.3–8.0 bn across the period, mostly right-of-use assets. A KRW 5 bn buyback was executed from November 2019 (Dealsite, 12 Feb 2020). For a VC, operating cash flow is distorted by the classification of investment purchases and disposals and is a poor indicator of earning power.

Ratios

Notes: TTM ROE at June 2026 is 13.86% (Valueline). TTM interest coverage at June 2026 is about 43x (derived: KRW 54.21 bn ÷ KRW 1.25 bn). ROIC, current ratio, net debt/EBITDA and cash conversion cycle are not meaningful or not reported for a financial company of this type.

Ratio commentary. Through FY2025, returns on equity in the low single digits were well below any reasonable cost of equity. This explains why the stock traded near or slightly above book (P/B 1.1–1.3x) despite large mark-to-market assets. The 1H 2026 profit lifted TTM ROE to about 14%. The key question for valuation is whether this is repeatable or a one-off crystallisation of SpaceX and Arcellx value.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Business Units

UnitContentKey people (as reported)

VC Investment Division

Domestic venture funds (Aju Good Venture Fund series, Super-Gap Scale-up funds, policy funds)

Park Gye-hoon, VC Investment Division head, also AC Division head (Asiae CORE, 27 Aug 2026); Yoon Chang-soo, Venture Investment 1 head per 2021 appointment (Dealsite, 7 Jan 2021)

Accelerator (AC) Division

Seed and early-stage investing; government-programme consulting; created January 2026

Park Gye-hoon (concurrent)

PE Investment Division

Aju Good PEF series (No.3 KRW 267.9 bn; No.4 KRW 316 bn); project funds (Aju E-Bridge Fund KRW 146.4 bn)

Kim Tae-seung appointed PE head in 2021 (Dealsite, 7 Jan 2021); former inside director Choi Yong-jin resigned in early 2025 (Dealsite, 27 Mar 2025).

Global Investment Division

Cross-border funds; Super-Gap Scale-up 2.0 lead manager

Managing Director Park Se-geun, formerly Samsung SDI, NC and IMM Investment (Dealsite, 22 Jul 2026)

Risk Management / Compliance

Risk, compliance officer function

Heo Byung-du, CPA (formerly Samil), appointed 2021 (Dealsite, 7 Jan 2021)

Solasta Ventures (Boston, US)

100%-owned subsidiary; life-sciences venture investing

Derek (Dong-min) Yoon, head of entity

Solasta Nexus (Silicon Valley, US)

Deep-tech investing (AI, robotics, space, cloud); branch since 2019, entity since June 2026

Michael Jeon, partner and head

Revenue by Segment

MetricFY2023FY2024FY2025

Fee income total (KRW Bn)

28.023.120.4

Performance fees (KRW Bn)

10.24.5—

Management and other fees, derived (KRW Bn)

17.818.6—

Net gains on financial instruments (KRW Bn)

——5.0

Net operating income (KRW Bn)

——28.0

Operating income (KRW Bn)

17.78.411.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Revenue by Segment (FY2024–2Q2026)

MetricFY20242Q2026

Venture fund AUM (KRW Bn)

1,387.51,398.3

PE fund AUM (KRW Bn)

687.91,150.2

Total AUM (KRW Bn)

2,075.42,548.5

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Operating revenue (KRW Bn)

139.263.473.765.6—

Operating income (KRW Bn)

52.04.817.78.411.9

Pre-tax income (KRW Bn)

————11.7

Net income (KRW Bn)

39.32.016.68.38.3

Basic EPS derived (KRW)

325171376969

Dividend per share (KRW)

————70

Operating margin on revenue (%)

37.47.624.012.8—

Net margin on revenue (%)

28.23.222.512.7—

Income Statement

MetricFY2018FY2019FY2020

Operating revenue (KRW Bn)

72.864.1146.2

Operating income (KRW Bn)

15.021.763.1

Net income (KRW Bn)

11.816.3—

Dividends & Capital Returns

Line item (KRW Bn)FY2025TTM to Jun-2026

Interest income

2.722.42

Interest expense

1.401.25

Fee income

20.3634.82

Gains on financial instruments

22.1355.89

Losses on financial instruments

17.1321.67

Dividend income

0.850.98

Net operating income

27.9970.80

SG&A

16.1016.59

Operating income

11.8854.21

Pre-tax income

11.7454.09

Income tax

3.4212.59

Net income

8.3141.49

Key Financials

MetricQ1-2024Q2-2024Q3-2024Q4-2024Q1-2025Q2-2025Q3-2025Q4-2025Q1-2026Q2-2026

Operating income (KRW Bn)

6.34.50.0-2.40.83.12.35.78.138.1

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY20252Q2026

Total assets (KRW Bn)

373.3354.6341.7338.3363.9

Cash and deposits (KRW Bn)

45.083.765.979.864.5

FVTPL financial assets (KRW Bn)

138.895.490.189.4129.7

Equity-method investments (KRW Bn)

155.1142.9152.3141.7144.0

Intangible assets (KRW Bn)

1.01.01.01.81.9

Goodwill (KRW Bn)

00000

Total liabilities (KRW Bn)

129.996.180.671.464.6

Total borrowing liabilities (KRW Bn)

95.660.251.243.930.3

Bank borrowings (KRW Bn)

28.024.024.024.016.0

Bonds (KRW Bn)

5.2002.60

Other borrowing liabilities (KRW Bn)

62.336.227.217.314.3

Deferred tax liabilities (KRW Bn)

13.311.08.08.215.0

Net debt derived (KRW Bn)

50.6-23.5-14.7-35.9-34.2

Shareholders' equity (KRW Bn)

243.4258.5261.1266.9299.3

Retained earnings (KRW Bn)

168.1182.4184.8187.2215.0

Treasury shares (KRW Bn)

-3.8-3.3-3.3-1.70

Book value per share derived (KRW)

2,0152,1392,1592,2032,470

Cash Flow

MetricFY2025TTM to Jun-2026

Operating cash flow (KRW Bn)

-1.120.7

Margin Analysis (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025

ROE on average equity derived (%)

—6.63.23.1

ROA on average assets derived (%)

—4.62.42.4

Borrowings to equity derived (%)

39.323.319.616.4

Total liabilities to equity derived (%)

53.437.230.926.8

Asset turnover derived (x)

—0.200.19—

Interest coverage OI to interest expense (x)

———8.5

Geographic Revenue

IndicatorFigureSource

Share of FY2020 investment gains from overseas

More than 30%

CEO statement, Dealsite, 2 Feb 2021

US portfolio companies listed on Nasdaq (cumulative)

19

Asiae CORE, 27 Aug 2026

Solasta portfolio as of Jan 2021

29 companies invested, 15 Nasdaq-listed

Dealsite, 26 Jan 2021

Boston-sourced exits: Arcellx, Kymera, Atea

KRW 32.3 bn invested → KRW 324.1 bn recovered (derived sum)

Asiae CORE, 27 Aug 2026

Planned annual US deployment (2019 plan)

KRW 30–50 bn per year, up from KRW 20–30 bn

Dealsite, 2 Jul 2019

Japan exposure

First LP commitment to Japanese VC funds in 2025

Asiae CORE, 27 Aug 2026

Share Price and Market Valuation

MetricFY2022FY2023FY2024FY2025

Year-end share price (KRW)

2,2152,7502,4302,885

Year-end market cap (KRW Bn)

267.6332.3293.9349.5

Year-end P/B (x)

—1.291.131.31

Year-end P/E derived (x)

13220.035.442.1

Share Price & Returns

PeriodReturn

Year-to-date (vs end-2025 KRW 2,885)

−2.9%

vs end-2024 (KRW 2,430)

+15.2%

vs end-2023 (KRW 2,750)

+1.8%

vs IPO price (KRW 1,500, Nov 2018)

+86.7%

vs 24 Apr 2026 peak close (KRW 18,720)

−85.0%

Valuation Multiples

MultipleAju IBBasis

P/E (TTM to Jun-2026)

~8.2x

NI TTM KRW 41.49 bn (derived)

P/E (FY2025)

~40.8x

NI KRW 8.31 bn (derived)

P/B (2Q 2026 equity)

~1.13x

Equity KRW 299.3 bn (derived)

P/B (FY2025 equity)

~1.27x

Equity KRW 266.9 bn (derived)

Peer reference

VC peer median P/B ~0.91x

AlphaDistill, 19 Aug 2026 (independent publication, not a broker)

Per-Share Data and Dividends & Capital Returns

MetricFY2018FY2019FY2025

Dividend per share (KRW)

253570

Total dividend (KRW Bn)

3.04.1—

Analyst Conclusions

Management guidance

There is no quantitative earnings guidance. Management's stated near-term agenda is to:

  • Complete the KRW 200 bn Super-Gap Scale-up 2.0 fund and the KRW 50 bn Frontier-Tech fund.

  • Harvest more than ten portfolio IPOs in 2H 2026.

  • Continue recurring exits and new investment to reward shareholders and LPs (Asiae, 14 Aug 2026).

Consensus growth expectations

None available (no coverage).

Bull case

  1. Normalised fee base is stepping up. AUM rose about 23% from end-2024 to 2Q 2026. New PE and policy funds should lift annual management fees above the ~KRW 18 bn FY2023–FY2024 level, raising the floor under earnings. TTM fee income was already KRW 34.8 bn.

  2. Hidden value at a low multiple. At ~1.1x book and ~8x TTM earnings, the market appears to assign little value to a SpaceX stake, residual AI positions (Lambda, Databricks, Cohere) and a full-cycle franchise with a documented ~10x US exit record.

  3. Cyclical tailwinds. Korean venture investment recovered to KRW 13.6 trn in 2025, with KRW 14.3 trn of fund formation. Together with the National Growth Fund and pension reforms, this favours large incumbents, and Aju IB already holds a GP slot.

Bear case

  1. 1H 2026 was a one-off. A large part of the record profit came from SpaceX fair-value gains and the Arcellx take-out. SpaceX fell ~50% from its peak within weeks of listing, so 2H 2026 marks could reverse part of the gain. Without these, core profitability has run at only KRW 8–12 bn of NI.

  2. Alignment and governance. The CEO sold ~94% of his shares and the parent sold 7% near the peak. With owner-family board seats, this weakens the minority-shareholder case and may keep a discount on the stock.

  3. Disclosure opacity and theme dependence. The undisclosed SpaceX cost and stake, plus zero sell-side coverage, mean the stock trades on themes rather than on fundamentals. The 8x rise and 85% fall within six months illustrate the resulting volatility.

Key catalysts and monitorables (next 12 months)

CatalystExpected timingWhat to watch
3Q 2026 resultsMid-November 2026Direction of SpaceX mark; performance fees; whether TTM ROE stays near 14%
Low-P/B company listFrom November 2026Whether Aju IB is listed; any value-up response (buybacks, dividend policy)
SpaceX lock-up expiry and realisationLate 2026 (timing not disclosed)Any disclosure of realised proceeds or distributions
Super-Gap Scale-up 2.0 close2H 2026Final size vs KRW 200 bn target; Teachers' Pension matching
Frontier-Tech fund close2026–27KRW 50 bn target
2H 2026 IPOsRollingDabeeo, PGT, MBD, NexI listings and post-IPO performance
E-Bridge integration2026–27Earnings growth; partnership announcements
FY2026 dividendFeb–Mar 2027Whether payout rises with record earnings
Parent shareholdingOngoingAny further sell-downs from 53.37%

Analyst verdict

Aju IB Investment is a credible, long-established Korean VC/PE manager. Its listed equity has been repriced twice in 2026. It first traded as a SpaceX proxy and then as a firm whose controlling shareholder and CEO sold into that rally.

The underlying business has improved materially. AUM reached KRW 2.55 trn in 2Q 2026. The PE franchise now carries a KRW 316 bn fund and a ~KRW 250 bn platform buyout. The US platform has produced roughly KRW 324 bn of realisations from just KRW 32 bn invested in three biotechs. The balance sheet carries net cash. 1H 2026 delivered OI of KRW 46.2 bn, more than four times FY2025's full-year figure.

The record result should nonetheless be treated as partly non-recurring. Through FY2025, the firm earned 3–7% returns on equity. Its fee base of roughly KRW 18–20 bn barely exceeded fixed costs of roughly KRW 16 bn in SG&A. Profit above breakeven depended on realisations that are inherently lumpy. The SpaceX gain is unrealised, its size is undisclosed, and the market value of the underlying stock has been volatile since listing.

At about KRW 2,800 per share (~1.1x book, ~8x TTM earnings), the valuation no longer reflects the April euphoria and is close to book. That is reasonable for a business whose sustainable ROE probably sits in the mid-to-high single digits, with upside if fee-bearing AUM keeps growing and the 2H 2026 IPO pipeline converts.

The stock is likely to remain a high-volatility, theme-driven instrument until two things change. First, management would need to disclose more about its largest positions. Second, the owner family would need to align more visibly with minority holders, through clearer capital-return policy or reduced selling. Investors should anchor on book value and recurring fees rather than on SpaceX headlines. The near-term tests are the 3Q 2026 mark-to-market and the close of the Super-Gap Scale-up 2.0 fund.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleBackgroundTenure / notesSource

Kim Ji-won (김지원)

CEO and inside director

Born 1967; Yonsei University (business administration); joined 1999 (then KIBO Capital)

CEO since Mar 2015; re-appointed Mar 2025 for 2 years (term to Mar 2027)

Dealsite, 6 Feb 2025 & 27 Mar 2025

Moon Kyu-young (문규영)

Non-standing director

Chairman, Aju Group

Re-appointed Mar 2024

Dealsite, 28 Mar 2024

Lee Hwang-cheol (이황철)

Non-standing director

CEO of (주)아주 since 2023; formerly Mercer Consulting (2006), Aju HR head (2013), Aju chief of staff (2015)

Appointed Mar 2024

Dealsite, 28 Mar 2024

Moon Yoon-hoe (문윤회)

Non-standing director

Born 1981; eldest son of Chairman Moon; CEO of Aju hotel division since 2009; CEO of (주)아주 Vision Community since 2023

Appointed Mar 2025 (2-year term); replaced resigned PE inside director Choi Yong-jin

Dealsite, 27 Mar 2025

Hwang Kyu-min (황규민)

Non-standing director

Lawyer, Hankyul Law Firm

Re-appointed Mar 2025

Dealsite, 27 Mar 2025 & 28 Mar 2024

Yoon Seok-jin (윤석진)

Outside director

Former president of KIST; reported as a designer of the Lee Jae-myung administration's science and technology policy

Serving as of Jun 2025

Dealsite, 5 Jun 2025

Han Chang-soo (한창수)

Outside director (audit committee)

Professor of psychiatry, Korea University College of Medicine; clinical-research and health-policy advisory background

Re-appointed Mar 2024

Dealsite, 28 Mar 2024

Third outside director

Outside director

———

Executive Leadership Team

NameTitleBackgroundSource

Park Gye-hoon (박계훈)

Head of VC Investment Division and AC Division

—

Asiae CORE, 27 Aug 2026

Park Se-geun (박세근)

Managing Director, Global Investment Division; lead manager of Super-Gap Scale-up 2.0

Samsung SDI, NC, IMM Investment; portfolio includes Lezhin Entertainment, Delicious, PNP

Dealsite, 22 Jul 2026

Jung Dae-seok (정대석)

Division head (본부장)

Sold 19,650 shares (~KRW 353 m) in Apr 2026

Dealsite, 21 Aug 2026

Yoon Chang-soo (윤창수)

Head, Venture Investment 1 (2021 appointment)

Joined 1999; sourced DTNC, Carver Korea, Actro

Dealsite, 7 Jan 2021

Heo Byung-du (허병두)

Head of Risk Management and compliance officer (2021)

CPA, formerly Samil PwC

Dealsite, 7 Jan 2021

Kim Tae-seung (김태승)

Head of PE Investment (2021)

Mirae Asset Daewoo, Deloitte Anjin; sourced Point Mobile

Dealsite, 7 Jan 2021

Derek (Dong-min) Yoon

Head, Solasta Ventures (Boston)

MSF, Boston College; MBA, Babson; RBS healthcare banking; Berwind Private Equity

Asiae CORE, 27 Aug 2026

Michael Jeon

Partner and head, Solasta Nexus

BS EECS, UC Berkeley; MS software engineering, Carnegie Mellon; MBA, MIT Sloan; ex-Samsung

Asiae CORE, 27 Aug 2026; Dealsite, 2 Jul 2019

Major Shareholders

HolderStakeNotesSource

(주)아주 (Aju Corporation)

53.37%

After block sale of 8,481,780 shares at KRW 18,700 (Apr 2026); previously 60.54%

AlphaDistill, 19 Aug 2026

CEO Kim Ji-won

~0.01% (12,416 shares)

Sold 187,584 of ~200,000 shares in Apr 2026

AI-Fortunate blog, Apr 2026; MarketScreener

Retail shareholders

~40,000 holders (Mar 2025)

—

Dealsite, 27 Mar 2025

Competitive Landscape

Key Competitors

CompetitorListingOverlap with Aju IBRelative positioning

Mirae Asset Venture Investment

KOSDAQ 100790

Large generalist VC; SpaceX holder; US/Asia platform

#1 listed VC by market cap (above KRW 2 trn, Jun 2026); direct SpaceX-theme peer

Korea Investment Partners

Unlisted (Korea Investment Holdings)

Largest domestic VC; global offices

Larger AUM; affiliated with a securities group

Atinum Investment

KOSDAQ 021080

Large generalist VC

#1 listed VC by FY2024 fees (KRW 46.9 bn); strong 2025

DSC Investment

KOSDAQ 241520

Early/growth VC; FuriosaAI

Deep-tech theme peer; buyback and cancellation in 2026

LB Investment

KOSDAQ 309960

Generalist VC; owner-family board

Comparable governance profile; strong 2025 realisations

Woori Technology Investment

KOSDAQ 041190

VC with Dunamu stake

#3 listed VC by market cap (KRW 459.5 bn, Jun 2026)

STIC Investments

KOSPI 026890

PE and growth

Competitor for PE LP capital

SBI Investment Korea

KOSDAQ 019550

VC

Smaller

TS Investment

KOSDAQ 246690

Growth, secondary, M&A; owns accelerator New Paradigm

Full-cycle model peer

IMM Investment

Unlisted

Large VC/PE; secondaries

Competitor for policy and pension mandates

Premier Partners

Unlisted

Biotech-strong VC/PE

Biotech competitor

Company K Partners, Stonebridge Ventures, Lindeman Asia, Nau IB Capital

KOSDAQ 307930 / 330730 / 277070 / 293580

Mid-sized VCs

Smaller-scale peers

Peer Comparison FY2024

MetricAju IBMirae Asset VentureAtinum InvestmentDSC Investment

9M 2025 operating revenue (KRW Bn)

—126.054.724.6

9M 2025 operating income (KRW Bn)

6.2 (derived)

12.931.46.1

9M 2025 OI growth YoY (%)

-43 (derived vs 10.8)

-39227-34

FY2024 management + performance fees (KRW Bn)

23.1 (fee income)

—46.926.9

AUM (KRW trn)

2.55 (2Q 2026)

—

~1.2 (2023 reference)

—

Company Snapshot

$48.1M

Revenue

53

Employees

1974

Founded

Seoul, South Korea

Headquarters

SWOT Analysis

Strengths

  • Record earnings power demonstrated. 1H 2026 OI of KRW 46.2 bn exceeded any full year since FY2021 (Asiae, 14 Aug 2026).
  • Proven US exit engine. Arcellx turned KRW 17.4 bn into KRW 167.5 bn; Kymera KRW 5.7 bn into KRW 64.1 bn; Atea KRW 9.2 bn into KRW 92.5 bn (Asiae CORE, 27 Aug 2026).
  • Growing AUM base. AUM rose from KRW 2.08 trn (end-2024) to KRW 2.55 trn (2Q 2026), supporting a recurring fee floor.
  • Strong balance sheet. Net cash of about KRW 34 bn (derived, 2Q 2026); borrowings to equity of 10% (derived).
  • Diversified LP franchise. NPS, KDB, Korea Eximbank, mutual-aid associations, the National Growth Fund and a committed parent.
  • Full-cycle model. AC Division (2026), VC funds and a KRW 316 bn PE fund executing a ~KRW 250 bn buyout.

Weaknesses

  • Structurally low ROE through cycles. 3.1–6.6% in FY2023–FY2025 (derived).
  • Earnings volatility. OI moved from KRW 52.0 bn to KRW 4.8 bn to KRW 17.7 bn to KRW 8.4 bn to KRW 11.9 bn (FY2021–FY2025).
  • Performance-fee dependence. Fees fell 56% in FY2024 when liquidations slowed (Dealsite, 16 May 2025).
  • Opaque disclosure. SpaceX cost and stake are undisclosed (Dealsite, 21 Aug 2026).
  • Governance. The eight-member board is half non-standing directors, with three owner-linked (Dealsite, 5 Jun 2025).
  • No sell-side coverage. Zero FnGuide reports as of 19 Aug 2026 (AlphaDistill).

Opportunities

  • SpaceX realisation after lock-up expiry could convert unrealised gains into cash and performance fees. Timing and size are not disclosed.
  • Super-Gap Scale-up 2.0 (KRW 200 bn target) and Frontier-Tech (KRW 50 bn) would add fee-bearing AUM.
  • KOSDAQ IPO pipeline. Dabeeo, PGT, MBD and NexI are among more than ten 2H 2026 candidates (Asiae, 14 Aug 2026).
  • E-Bridge value creation. Asia-Pacific air-travel growth and potential IPO exit (Dealsite, 11 Feb 2026).
  • Expanding policy capital. The KRW 150 trn National Growth Fund and pension-to-venture rules.
  • AI portfolio. Lambda, Databricks and Cohere positions could produce further US exits.

Threats

  • SpaceX mark-to-market reversal. Shares fell ~50% from the post-IPO peak by late July 2026, putting 1H 2026 gains at risk of reversal (Wikipedia).
  • Overhang. Parent block sales (2021, 2026) and insider selling weigh on sentiment (Dealsite, 21 Aug 2026).
  • KOSDAQ dependence. KOSDAQ fell from above 900 to the 600s in 2024 and triggered losses (Dealsite, 22 Nov 2024).
  • Regulatory trading actions. Investment-warning designations and short-selling overheated designations in 2026.
  • Upcoming low-P/B list. The government will publish a low-P/B company list from November 2026 (Dealsite, 21 Aug 2026).
  • Competition. Mirae Asset Venture, Atinum and DSC are competing for the same policy and pension mandates.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
9 Apr 2025Shares hit a year-low of ~KRW 1,924 amid tariff-driven sell-off Dealsite, 5 Jun 2025Cycle trough
15–16 May 20251Q 2025 OI of KRW 0.77 bn (−88% YoY); management outlines ~KRW 500 bn fundraising plan Dealsite, 16 May 2025Earnings trough; AUM strategy
May 2025Organoid Sciences lists on KOSDAQ, ~80% above IPO price by mid-May; Inventage Lab rises ~230% from March Dealsite, 16 May 2025Mark-up support
1Q 2025Liquidation of Aju Digital Contents Fund (KRW 26 bn) and IBKC-Aju IDiscovery (KRW 7.2 bn) Dealsite, 16 May 2025Fund lifecycle
Jun 2025Outside director Yoon Seok-jin linked to new government's science policy; share jumps ~7% Dealsite, 5 Jun 2025Governance and political sentiment
Jun 2025Company confirms Frontier-Tech fund (KRW 50 bn) fundraising Asiae CORE, 18 Jun 2025US deep-tech expansion
2025First LP commitments to Japanese VC funds Asiae CORE, 27 Aug 2026Geographic diversification
Dec 2025Aju Good No.4 PEF first close (~KRW 300 bn); E-Bridge SPA signed Dealsite, 11 Feb 2026Largest PE fund; first platform buyout
Jan 2026Accelerator unit elevated to division Asiae CORE, 27 Aug 2026Early-stage push
3 Feb 2026Shares +14% to KRW 5,110 on SpaceX IPO momentum Asiae CORE, 3 Feb 2026SpaceX theme ignition
Feb 2026Up ~455% YTD; KRX gives investment-warning notice Newsis, 26 Apr 2026Regulatory caution
11 Feb 2026Dealsite reports E-Bridge closing scheduled for April Dealsite, 11 Feb 2026PE expansion
23–27 Feb 2026Gilead agrees to buy Arcellx for USD 7.8 bn; Aju shares +~30% Asiae, 27 Feb 2026~10x exit crystallisation
Mar 2026No.4 PEF second close at KRW 316 bn; Aju E-Bridge Fund (KRW 146.4 bn) formed Asiae, 14 Aug 2026AUM growth
1 Apr 2026Close of KRW 9,370 after +29.9% on 25 March Asiae CORE, 6 Apr 2026SpaceX filing momentum
24 Apr 2026Peak close of KRW 18,720; P/B 8.49x Dealsite, 21 Aug 2026Valuation extreme
21–28 Apr 2026CEO sells ~94% of his stake (~KRW 2.39 bn); division head sells ~KRW 353 m Dealsite, 21 Aug 2026Insider-sale overhang
28–29 Apr 2026Parent announces 7% block sale at KRW 18,700 (~KRW 158.6 bn); shares fall nearly 20% Herald, 28 Apr 2026Overhang realised
May–Jun 2026National Growth Fund GP selection; shares ~KRW 10,180 on 4 June JKN, 4 Jun 2026Policy capital
10 & 17 Jun 2026Major-shareholder and insider holding-change filings Butler filing listOwnership changes
12 Jun 2026SpaceX lists on Nasdaq at USD 135; first-day close USD 161 Reuters via Chronicle.lu; WikipediaRealisation path for SpaceX stake
Jun 2026Solasta Nexus incorporation completed Asiae CORE, 27 Aug 2026US platform build-out
9 Jun 2026Ranked #2 listed VC by market cap behind Mirae Asset Venture Asiae CORE, 10 Jun 2026Peer standing
Jul 2026Lemon Healthcare IPO; dry powder down to KRW 134.5 bn after ~KRW 150 bn deployed Asiae, 14 Aug 2026; Dealsite, 22 Jul 2026Exits and redeployment
Late Jul 2026SpaceX shares ~50% below post-IPO peak Wikipedia (SpaceX IPO)Mark-to-market risk
12 Aug 2026Delicious IPO Asiae, 14 Aug 2026Exit
13 Aug 2026Aju IB +29.89% limit-up to KRW 4,585 on SpaceX rebound AlphaDistill, 14 Aug 2026Theme volatility
14 Aug 20261H 2026 results: record OI of KRW 46.2 bn; AUM ~KRW 2.5 trn Asiae, 14 Aug 2026Earnings inflection
14–18 Aug 2026Short-selling overheated designation for three sessions AlphaDistill, 19 Aug 2026Regulatory
20–21 Aug 2026Dealsite highlights insider selling and P/B compression (8.5x → 1.84x) Dealsite, 21 Aug 2026Governance and valuation scrutiny
27 Aug 2026Asiae deep-dive: 2Q 2026 AUM KRW 2.5485 trn; 19 Nasdaq listings Asiae CORE, 27 Aug 2026Platform validation
16 Sep 2026Featured on MTN as a SpaceX / IPO-recovery trading pick MTN, 16 Sep 2026Retail-driven trading
8 Oct 2026Shares ~KRW 3,540; 52-week range KRW 1,913–19,950 StockHubPrice discovery
15 Oct 2026Shares ~KRW 2,800 (−8.65% intraday) ValuelineNew post-peak low area

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Revenue by Segment (FY2023–FY2025): Fee income total fell from KRW 28,000 Mn in FY2023 to KRW 20,400 Mn in FY2025.
Aju IB Investment Co., Ltd. — Revenue by Segment (FY2023–FY2025)
Series (KRW Mn)FY2023FY2024FY2025
Fee income total28,00023,10020,400
Performance fees10,2004,500—
Management and other fees17,80018,600—
Net gains on financial instruments——5,000
Net operating income——28,000
Operating income17,7008,40011,900

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Valueline / DataHero — Aju IB (027360) consolidated income statement, balance sheet and cash flow pages (data through 2Q 2026; quote 15 Oct 2026)
  2. Butler — company page 00156895 (FY2021–FY2025 headline financials; filing list; revenue mix)
  3. Dealsite — articles 17723, 24235, 24637, 50183, 56984, 67393, 69543, 70234, 70517, 73091, 118016, 120275, 123116, 126947, 126969, 131819, 135954, 136558, 138917, 141161, 141642, 142584, 156623, 165464, 166469 (2019–2026)
  4. Asia Economy / Asiae CORE — 14 Nov 2024; 3 Dec 2024; 16 May 2025 (English); 18 Jun 2025; 17 Nov 2025; 3 Feb 2026; 27 Feb 2026; 6 Apr 2026; 10 Jun 2026; 14 Aug 2026; 27 Aug 2026
  5. Aju News (5 Apr 2018): Hankyung (25 Apr 2018; 19 Nov 2020) · NewDaily (7 Nov 2018) · Asia Today (26 May 2011) · MTN (16 Apr 2021; 16 Sep 2026) · Herald (28 Apr 2026) · Newsis (13 Feb 2026; 26 Apr 2026) · JKN (4 Jun 2026) · Newstomato / IB Tomato (12 Mar, 24 Mar, 18 Feb 2026) · Money Today (24 Mar 2025) · Hellot (Feb 2026) · Byline Network (12 Feb 2025)
  6. THE VC (Aju IB and Solasta Ventures profiles): CB Insights investor profile · MarketScreener (Kim Ji-won insider page)
  7. StockHub (8 Oct 2026): ETFShopping (Aug & Oct 2026) · AlphaDistill (14 & 19 Aug 2026, independent publication) · AI-Fortunate blog (Apr 2026)
  8. Reuters via Chronicle.lu (11 Jun 2026): Business Today (12 Jun 2026) · Wikipedia — Initial public offering of SpaceX
  9. Mirae Asset Daewoo company report on Aju IB (20 May 2019)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.